REGISTER
ATS 2026:New COPD Trials and What Comes Next
Prof. Rabe highlights the underdiagnosis of COPD and severe asthma, emerging biologic therapies targeting cytokines and alarmins, and calls for earlier detection and cross-specialty collaboration in chronic respiratory disease management.

Prof. Klaus F. Rabe, Director of Pneumology, LungClinic Grosshansdorf, University of Kiel, Germany Chronic lung diseases including COPD and severe asthma remain underdiagnosed, with most patients identified only after significant disease progression. At ATS 2026 in Orlando, Prof. Rabe discusses emerging biologics and cytokine-targeting therapies, including trials focused on alarmins as a novel pathway in COPD pathogenesis. He also highlights three pressing challenges: the persistent burden of lung cancer, the need for early detection in at-risk populations, and the importance of cross-specialty collaboration in managing chronic respiratory disease.

0
0
Loading